Insights - Today La Jolla (LJPC) announced Q2 results for Giapreza and numbers were very underwhelming. For the three months ended June 30, 2020, U.S. sales of Giapreza were $5.8 … Continue Reading
Premium: Read NowInsights - Fennec filed a trademark for their “PEDMARK” drug today. This is a good sign as Fennec is preparing for commercialization (and therefore FDA approval) of Pedmark. Fennec’s … Continue Reading
Premium: Read NowInsights - Essa (EPIX) announced an offering after market today. Although details on amount and pricing have not yet been disclosed, we think there will be strong … Continue Reading
Premium: Read NowInsights - Yesterday Essa (EPIX) announced it dosed the first patient in their Phase 1 mCRPC study. EPIX is up 30% since we first covered it back in late … Continue Reading
Premium: Read NowInsights - AC Immune (ACIU) is up 60% in pre-market after the company announced it was advancing their anti-tau vaccine in Alzheimer’s Disease (AD) to higher dosing cohorts. Although … Continue Reading
Read NowInsights - Magenta (MGTA) is pursuing two of the largest challenges in stem cell transplants; mobilizing stem cells and conditioning patients for transplants. Overcoming these challenges will … Continue Reading
Premium: Read NowInsights - Bellus announced Phase 2 data this morning and it was a major flop. The stock is down 75%. Bellus did not hit statistical significance in any of … Continue Reading
Premium: Read Now
